Terms: = Skin cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Prognosis
217 results:
1. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
[TBL] [Abstract] [Full Text] [Related]
2. Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
[TBL] [Abstract] [Full Text] [Related]
3. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract] [Full Text] [Related]
4. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract] [Full Text] [Related]
5. Systematic Multiomic Analysis of
Kang JY; Yang J; Lee H; Park S; Gil M; Kim KE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203530
[TBL] [Abstract] [Full Text] [Related]
6. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
7. Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma.
Usta SZ; Uchihashi T; Kodama S; Kurioka K; Inubushi T; Shimooka T; Sugauchi A; Seki S; Tanaka S
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139110
[TBL] [Abstract] [Full Text] [Related]
8.
Xie Y; Li Y; Yang M
J Immunol Res; 2023; 2023():5041223. PubMed ID: 38125697
[No Abstract] [Full Text] [Related]
9. Association between immune-related adverse events and prognosis in patients treated with immune checkpoint inhibitors in melanoma: A surrogacy analysis.
Euvrard R; Robert M; Mainbourg S; Dalle S; Lega JC
Fundam Clin Pharmacol; 2024 Apr; 38(2):369-379. PubMed ID: 38012082
[TBL] [Abstract] [Full Text] [Related]
10. Mechanisms and biomarkers of immune-related adverse events in gastric cancer.
Ding P; Liu P; Meng L; Zhao Q
Eur J Med Res; 2023 Nov; 28(1):492. PubMed ID: 37936161
[TBL] [Abstract] [Full Text] [Related]
11. Construction of a novel prognostic model in skin cutaneous melanoma based on chemokines-related gene signature.
Ding X; Wang W; Tao X; Li Z; Huang Y
Sci Rep; 2023 Oct; 13(1):18172. PubMed ID: 37875556
[TBL] [Abstract] [Full Text] [Related]
12. The immune checkpoint VISTA is associated with prognosis in patients with malignant uveal melanoma.
Issam Salah NEI; Marnissi F; Lakhdar A; Karkouri M; ElBelhadji M; Badou A
Front Immunol; 2023; 14():1225140. PubMed ID: 37662962
[TBL] [Abstract] [Full Text] [Related]
13. HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma.
Li L; Tianrui K; Chunlei L; Zhendong Q; Xiaoyan C; Wenhong D
Aging (Albany NY); 2023 Aug; 15(16):7997-8012. PubMed ID: 37595251
[TBL] [Abstract] [Full Text] [Related]
14. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.
Lepper A; Bitsch R; Özbay Kurt FG; Arkhypov I; Lasser S; Utikal J; Umansky V
Oncoimmunology; 2023; 12(1):2247303. PubMed ID: 37593676
[TBL] [Abstract] [Full Text] [Related]
15. SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.
An F; Zhang W; Guo Y; Shi F; Kong Y; Tang L; Han C; Wang Q
Aging (Albany NY); 2023 Aug; 15(15):7476-7495. PubMed ID: 37535001
[TBL] [Abstract] [Full Text] [Related]
16. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
Ascierto PA; Agarwala SS; Warner AB; Ernstoff MS; Fox BA; Gajewski TF; Galon J; Garbe C; Gastman BR; Gershenwald JE; Kalinski P; Krogsgaard M; Leidner RS; Lo RS; Menzies AM; Michielin O; Poulikakos PI; Weber JS; Caracò C; Osman I; Puzanov I; Thurin M
J Transl Med; 2023 Jul; 21(1):508. PubMed ID: 37507765
[TBL] [Abstract] [Full Text] [Related]
17. Molecular Mechanisms of Cutaneous Immune-Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitors.
Teng YS; Yu S
Curr Oncol; 2023 Jul; 30(7):6805-6819. PubMed ID: 37504358
[TBL] [Abstract] [Full Text] [Related]
18. TIGIT, a novel immune checkpoint therapy for melanoma.
Tang W; Chen J; Ji T; Cong X
Cell Death Dis; 2023 Jul; 14(7):466. PubMed ID: 37495610
[TBL] [Abstract] [Full Text] [Related]
19. Melanoma-the therapeutic considerations in the clinical practice.
Adeleke S; Okoli S; Augustine A; Galante J; Agnihotri A; Uccello M; Ghose A; Moschetta M; Boussios S
Ann Palliat Med; 2023 Nov; 12(6):1355-1372. PubMed ID: 37431221
[TBL] [Abstract] [Full Text] [Related]
20. Low-grade adenosquamous carcinoma of the breast: A rare case presentation.
Abrari A; Shehwar D; Akhtar K
J Cancer Res Ther; 2023; 19(2):480-483. PubMed ID: 37313920
[TBL] [Abstract] [Full Text] [Related]
[Next]